Sugi Predict

Sugi Predict / Targets / RAMP2

RAMP2

Receptor activity-modifying protein 2 (Calcit · O60895 · RAMP2 on Sugi Atlas →

331 patent compounds predicted against RAMP2, 296 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Pramlintide Pramlintide (SCHEMBL29355376) 1.00 1/20
Pramlintide Pramlintide (SCHEMBL29354060) 0.99 1/20
SCHEMBL30078470 SCHEMBL30078470 0.91 1/20
Davalintide Davalintide (SCHEMBL29377013) 0.85 1/20
SCHEMBL31692974 SCHEMBL31692974 0.82 1/20
SCHEMBL374892 SCHEMBL374892 0.78 1/20
Davalintide Davalintide (SCHEMBL29533482) 0.77 1/20
SCHEMBL29854921 SCHEMBL29854921 0.77 1/20
SCHEMBL2905167 SCHEMBL2905167 0.76 1/20
Amylin Amylin (SCHEMBL29351499) 0.75 1/20
SCHEMBL29720295 SCHEMBL29720295 0.73 1/20
SCHEMBL29374480 SCHEMBL29374480 0.73 1/20
SCHEMBL29419171 SCHEMBL29419171 0.71 1/20
SCHEMBL29511605 SCHEMBL29511605 0.71 1/20
SCHEMBL30362627 SCHEMBL30362627 0.70 1/20
SCHEMBL30299016 SCHEMBL30299016 0.69 1/20
Calcitonin Salmon Calcitonin Salmon (SCHEMBL29360745) 0.69 1/20
SCHEMBL29519841 SCHEMBL29519841 0.69 1/20
SCHEMBL29357151 SCHEMBL29357151 0.68 1/20
SCHEMBL238214 SCHEMBL238214 0.68 1/20

Clinical trials — most relevant to RAMP2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury PHASE3COMPLETED
The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients PHASE3UNKNOWN
Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial PHASE2/PHASE3UNKNOWN
Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension PHASE2COMPLETED
Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease PHASE2ACTIVE_NOT_RECRUITING
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
Safety and Efficacy Study of PEA and Polydatin on Intestinal Inflammation and Visceral Hyperalgesia in IBS Patients PHASE2UNKNOWN
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects PHASE2COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications PHASE1UNKNOWN
Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study PHASE1UNKNOWN
Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans PHASE1COMPLETED
PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A EARLY_PHASE1COMPLETED
Selective Activation of the Adrenomedullin Receptors in Migraine nanNOT_YET_RECRUITING
Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure nanUNKNOWN
Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments nanRECRUITING
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment nanNOT_YET_RECRUITING
PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load nanCOMPLETED
CGRP Induced Migraine Attacks in Patients With High and Low Genetic Load nanCOMPLETED
Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19). nanCOMPLETED
Genetic Architecture of Chronic Inflammatory Demyelinating Polyradiculoneuropathy nanUNKNOWN
Genetic Characterization of Parkinson's Disease nanCOMPLETED
BIOmarkers of MIGraine: a Proof of Concept Study Based on the Stratification of Responders to CGRP Monoclonal Antibodies nanCOMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins. nanUNKNOWN
Novel Biomarkers in Inflammatory Bowel Disease nanCOMPLETED
Molecular & Clinical Evaluation of Low HDL Syndromes nanCOMPLETED
A Multicenter Phenotype-Genotype Analysis of LGMD Patients in China nanENROLLING_BY_INVITATION
Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK) nanCOMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus nanUNKNOWN
Pain Predict Genetics nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a RAMP2 binder may also engage these)

ProteinNameSimilarity
Q8R4C5 — 0.990 Q8R4C5 →
Q9JHJ1 — 0.988 Q9JHJ1 →
Q9WUP0 — 0.988 Q9WUP0 →
Q9WTJ5 — 0.979 Q9WTJ5 →
Q9JJ74 — 0.979 Q9JJ74 →
RAMP1 Receptor activity-modifying protein 1 (Calcit 0.977 landscape →
Q867C0 — 0.976 Q867C0 →
Q8R4C6 — 0.973 Q8R4C6 →
Q8R4C4 — 0.970 Q8R4C4 →
Q8BGT0 — 0.970 Q8BGT0 →
Q9WUP1 — 0.969 Q9WUP1 →
Q86WC4 — 0.963 Q86WC4 →
O19131 — 0.963 O19131 →
P50555 — 0.962 P50555 →
Q7YS88 — 0.962 Q7YS88 →
P97260 — 0.961 P97260 →
O76095 — 0.961 O76095 →
Q5MNU5 — 0.961 Q5MNU5 →
Q6GQT6 — 0.960 Q6GQT6 →
Q68US5 — 0.960 Q68US5 →
Q12770 — 0.959 Q12770 →
A6QM06 — 0.959 A6QM06 →
Q5T848 — 0.959 Q5T848 →
A2RRU4 — 0.959 A2RRU4 →
D4A6L0 — 0.959 D4A6L0 →
RAMP3 Receptor activity-modifying protein 3 (Calcit 0.958 landscape →
E1BBQ2 — 0.958 E1BBQ2 →
Q6UWJ8 — 0.958 Q6UWJ8 →
Q3URD2 — 0.958 Q3URD2 →
Q6AZ51 — 0.958 Q6AZ51 →